Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders

The Ademi Firm is investigating Kronos (Nasdaq: KRON) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, shareholders of Kronos will receive only $0.57 per share, plus one contingent value right, which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Kronos’s product candidates known as KB-9558 and KB-7898 that occurs within 2 years following closing; (ii) 100% of the net proceeds in the case of a disposition of the Company’s product candidates known as KB-0742, lanraplenib and entospletinib that occurs prior to closing; (iii) 100% of cost savings realized prior to closing; (iv) 80% of cost savings realized between the merger closing date and the second (2nd) anniversary of the merger closing date; and (v) 50% of cost savings realized between the second (2nd) anniversary of the merger closing date and the third (3rd) anniversary of the merger closing date.

Kronos insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Kronos by imposing a significant penalty if Kronos accepts a competing bid. We are investigating the conduct of the Kronos board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250501808874/en/